References
Kaplan A, Ledford D, Ashby M, Canvin J, Zazzali JL, Conner E et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 2013;132:101–9
Kowalzick L, Eickenscheidt L, Pfeiffer AK, Pönnighaus JM, Surber C. Erfolgreiche multimodale Therapie der Licht-Urtikaria. Akt Dermatol 2013;39:83–6
Güzelbey O, Ardelean E, Magerl M, Zuberbier T, Maurer M, Metz M. Successful treatment of solar urticaria with anti-immunglobulin E therapy. Allergy 2008;63:1563–5
Waibel KH, Reese DA, Hamilton RG, Devillez RL. Partial improvement of solar urticaria after omalizumab. J Allergy Clin Immunol 2010;125:490–1
Duchini G, Bäumler W, Bircher AJ, Scherer K. Failure of omalizumab (Xolair®) in the treatment of solar urticaria caused by ultraviolett A and visible light. Photodermatol Photoimmunol Photomed 2011;27:336–7
Müller S, Schempp CM, Jakob T. Failure of omalizumab in the treatment of solar urticaria. J Eur Acad Dermatol Venereol 2016; 30:524–5
Baliu-Piqué C, Aguilera Peiró P. Three cases of solar urticaria successfully treated with omalizumab. J Eur Acad Dermatol Venereol 2016;30:704–6
Arasi S, Crisafulli G, Caminiti L, Guarneri F, Aversa T, Porcaro F et al. Treatment with omalizumab in a 16-year-old Caucasian girl with refractory solar urticaria. Pediatr Allergy Immunol 2015;26:583–5
Levi A, Tal Y, Dranitzki Z, Shalit M, Enk CD. Successful omalizumab treatment of severe solar urticaria in a 6-year-old child. Pediatr Allergy Immunol 2015;26:588–90
Metz M, Ohanyan T, Church MK, Maurer M. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticarial: a retrospective clinical analysis. J Derm Sci 2014;73:57–62
Metz M, Altrichter S, Ardelan E, Keßler B, Krause K, Magerl M et al. Anti-immunglobulin E treatment of patients with recalcitrant physical urticaria. Int Arch Allergy Immunol 2011,154:177–80
Author information
Authors and Affiliations
Corresponding author
Additional information
Conflict of interest
Prof. Dr. Kowalzick is a clinical investigator for Novartis Pharma.
Cite this as
Kowalzick L. Omalizumab for the treatment of solar urticaria: many questions remain unresolved. Allergo J Int 2016;25:96–7 DOI: 10.1007/s40629-016-0111-7
Rights and permissions
About this article
Cite this article
Kowalzick, L. Omalizumab for the treatment of solar urticaria: many questions remain unresolved. Allergo J Int 25, 96–97 (2016). https://doi.org/10.1007/s40629-016-0114-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40629-016-0114-4